Congress is back in session with a loaded agenda for the lame duck period. One of the top issues the life sciences industry is tracking is the potential passage of the BIOSECURE Act. Speaker Johnson has signaled the House...more
11/20/2024
/ Biotechnology ,
Congressional Committees ,
Grandfathering Rules ,
Healthcare ,
Lame Duck Session ,
Legislative Agendas ,
Life Sciences ,
Pending Legislation ,
Proposed Legislation ,
Senate Committees ,
U.S. House
Donald Trump will be the 47th President of the U.S. Not since 1892 has a President been elected to two non-consecutive terms, and his victory has helped Republicans pick up several critical seats in Congress. Senate...more
11/8/2024
/ Centers for Medicare & Medicaid Services (CMS) ,
Congressional Committees ,
Department of Health and Human Services (HHS) ,
Donald Trump ,
Election Results ,
Healthcare ,
Healthcare Reform ,
Lame Duck Session ,
Legislative Agendas ,
Members of Congress ,
Presidential Elections ,
Regulatory Agenda ,
Senate Committees ,
Trump Administration
Six months into the fiscal year, Congress has finally passed FY2024 appropriations. It was a painstaking process, which many expected to include policy victories that both sides could celebrate. Instead, the spring work...more
4/9/2024
/ Artificial Intelligence ,
Biotechnology ,
Congressional Committees ,
Coronavirus/COVID-19 ,
Healthcare ,
Healthcare Reform ,
Legislative Agendas ,
Medicare ,
Mental Health ,
New Legislation ,
Pandemic ,
Pharmaceutical Industry ,
Pharmacy Benefit Manager (PBM) ,
Prescription Drugs ,
Proposed Legislation ,
Telehealth ,
Transparency
This is the sixth in our 2024 Year in Preview series examining important trends in white collar law and investigations in the coming year. We will be posting further installments in the series throughout the next several...more
3/8/2024
/ China ,
Corporate Governance ,
Critical Infrastructure Sectors ,
Drug Pricing ,
Educational Institutions ,
Energy Projects ,
Environmental Social & Governance (ESG) ,
Healthcare ,
Legislative Agendas ,
Medicare Advantage ,
New Legislation ,
New Regulations ,
Pharmaceutical Industry ,
Private Equity ,
Regulatory Agenda ,
Social Media ,
Supply Chain ,
Supply Shortages ,
White Collar Crimes
Congressional Activity -
The challenges around addressing health concerns related to per- and polyfluoroalkyl substances (PFAS) are immense. The Environmental Protection Agency (EPA) states that PFAS are widely used, long...more
Fresh on the heels of intense optimism over the Department of Health and Human Services’ recommendation that cannabis be rescheduled, another key federal reform is in motion. On September 27, 2023, the Senate Committee will...more
9/26/2023
/ Banking Acts ,
Banking Sector ,
Cannabis Products ,
Cannabis-Related Businesses (CRBs) ,
Department of Health and Human Services (HHS) ,
FDIC ,
Legislative Agendas ,
Marijuana ,
Marijuana Related Businesses ,
Popular ,
SAFE ,
Senate Banking Committee
On July 27, 2023, House Energy and Commerce Committee Chair Cathy McMorris Rodgers (R-WA) and Ranking Member Frank Pallone, Jr., (D-NJ), along with Senate Health, Education, Labor, and Pensions (HELP) Committee Chair Bernie...more
On the heels of a January 2023 statement released by the FDA expressing the need for a new regulatory pathway for cannabidiol products, two CBD-related bills were reintroduced in the House of Representatives on March 17,...more
On February 27, 2021, the House of Representatives approved the H.R. 1319, the American Rescue Plan Act of 2021. This package comprises the $1.9 trillion proposal from the White House and Congressional Democrats who intend to...more